Highlights newsletter 2
This newsletter presents you the following key sessions:
2. Factor XI Antisense Oligonucleotide reduces the thrombosis risk without increased bleeding incidence
4. Adding vosaroxin to cytarabine suggests survival benefit in aggressive acute myeloid leukemia
5. Checkpoint inhibitors are effective in the treatment of Hodgkin’s Lymphoma